| pubmed-article:17419956 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C0242383 | lld:lifeskim |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:17419956 | lifeskim:mentions | umls-concept:C1576729 | lld:lifeskim |
| pubmed-article:17419956 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17419956 | pubmed:dateCreated | 2007-4-10 | lld:pubmed |
| pubmed-article:17419956 | pubmed:abstractText | Effectively evaluating disease-modifying effects in clinical trials has posed a problem for clinical trialists and drug development. One method that has been proposed to evaluate disease-modifying effects has been the re-randomization of active group participants to discontinue the intervention after a period sufficient to produce therapeutic effects. We aimed to determine if this design would permit inferences regarding disease modification in a trial evaluating Pegaptanib sodium, an intra-ocular injection, for the treatment of age-related macular degeneration. | lld:pubmed |
| pubmed-article:17419956 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17419956 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17419956 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17419956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17419956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17419956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17419956 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17419956 | pubmed:month | May | lld:pubmed |
| pubmed-article:17419956 | pubmed:issn | 0895-4356 | lld:pubmed |
| pubmed-article:17419956 | pubmed:author | pubmed-author:GuyattGordonG | lld:pubmed |
| pubmed-article:17419956 | pubmed:author | pubmed-author:KellyStevenS | lld:pubmed |
| pubmed-article:17419956 | pubmed:author | pubmed-author:MillsEdwardE | lld:pubmed |
| pubmed-article:17419956 | pubmed:author | pubmed-author:Heels-Ansdell... | lld:pubmed |
| pubmed-article:17419956 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17419956 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:17419956 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17419956 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17419956 | pubmed:pagination | 456-60 | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:meshHeading | pubmed-meshheading:17419956... | lld:pubmed |
| pubmed-article:17419956 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17419956 | pubmed:articleTitle | A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects. | lld:pubmed |
| pubmed-article:17419956 | pubmed:affiliation | Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. millsej@mcmaster.ca | lld:pubmed |
| pubmed-article:17419956 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17419956 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17419956 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17419956 | lld:pubmed |
